Answers are grounded in this paper and cite their sources.
Human RAD9 protein (hRAD9) is a homolog of the fission yeast Rad9 protein, one of the six so-called checkpoint Rad proteins involved in the early steps of DNA damage checkpoint response in Schizosaccharomyces pombe. It has been shown previously that, in vivo, a highly modified form of hRAD9 makes a ternary complex with two other checkpoint Rad proteins, hRAD1 and hHUS1 (Volkmer, E., and Karnitz, L. M. (1999) J. Biol. Chem. 274, 567–570; St. Onge, R. P., Udell, C. M., Casselman, R., and Davey, S. (1999) Mol. Biol. Cell. 10, 1985–1995). However, the function of this complex is not known at present. To help define the functions of checkpoint Rad proteins in humans, we expressed hRAD9 in Escherichia coli, purified the recombinant protein and characterized it. We found that hRAD9 is a 3′ to 5′ exonuclease and located the nuclease active site to the region between residues 51 and 91 of the 391-amino acid-long protein. Our results suggest that exonucleolytic processing of primary DNA lesion by hRAD9 may contribute to DNA damage checkpoint response in humans. Human RAD9 protein (hRAD9) is a homolog of the fission yeast Rad9 protein, one of the six so-called checkpoint Rad proteins involved in the early steps of DNA damage checkpoint response in Schizosaccharomyces pombe. It has been shown previously that, in vivo, a highly modified form of hRAD9 makes a ternary complex with two other checkpoint Rad proteins, hRAD1 and hHUS1 (Volkmer, E., and Karnitz, L. M. (1999) J. Biol. Chem. 274, 567–570; St. Onge, R. P., Udell, C. M., Casselman, R., and Davey, S. (1999) Mol. Biol. Cell. 10, 1985–1995). However, the function of this complex is not known at present. To help define the functions of checkpoint Rad proteins in humans, we expressed hRAD9 in Escherichia coli, purified the recombinant protein and characterized it. We found that hRAD9 is a 3′ to 5′ exonuclease and located the nuclease active site to the region between residues 51 and 91 of the 391-amino acid-long protein. Our results suggest that exonucleolytic processing of primary DNA lesion by hRAD9 may contribute to DNA damage checkpoint response in humans. human RAD9 protein polymerase chain reaction maltose-binding protein polyacrylamide gel electrophoresis nucleotide(s) DNA damage checkpoints are the biochemical pathways that stop cell cycle progression, when the DNA contains damage (1.Hartwell L.H. Kastan M.B. Science. 1994; 266: 1821-1828Crossref PubMed Scopus (2292) Google Scholar, 2.Elledge S.J. Science. 1996; 274: 1664-1672Crossref PubMed Scopus (1751) Google Scholar, 3.Russell P. Trends Biochem. Sci. 1998; 24: 399-402Abstract Full Text Full Text PDF Scopus (104) Google Scholar). The checkpoints help maintain genomic integrity by preventing replication of damaged DNA and inhibiting cell division before the generation of two genome complements. Conceptually, DNA damage checkpoints have three components, damage sensors, signal transducers, and effecter molecules. Genetic studies in Schizosaccharomyces pombe have identified six checkpoint Rad proteins (Rad1, Rad3, Rad9, Rad17, Rad26, and Hus1), which are required to regulate both the DNA replication and DNA damage checkpoints (3.Russell P. Trends Biochem. Sci. 1998; 24: 399-402Abstract Full Text Full Text PDF Scopus (104) Google Scholar, 4.Brondello J.M. Boddy M.N. Furnari B. Russell P. Mol. Cell. Biol. 1999; 19: 4262-4269Crossref PubMed Scopus (91) Google Scholar). There are very little biochemical data available on these proteins at present. The human ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia andrad3+ -related) proteins, which are phosphatidylinositol 3-kinase-related protein kinases, are considered to be the functional homologs of the S. pombe Rad3 protein (5.Savitsky K. Bar-Shira A. Gilad S. Rotman G. Ziv Y. Vanagaite L. Tagle D.A. Smith S. Uziel T. Sfez S. et al.Science. 1995; 268: 1749-1753Crossref PubMed Scopus (2345) Google Scholar) and to transmit DNA damage signal by phosphorylating downstream targets. Biochemical data on the other checkpoint Rad proteins are scarce. However, genetic data indicate that they function in the early steps of the checkpoint response (3.Russell P. Trends Biochem. Sci. 1998; 24: 399-402Abstract Full Text Full Text PDF Scopus (104) Google Scholar, 4.Brondello J.M. Boddy M.N. Furnari B. Russell P. Mol. Cell. Biol. 1999; 19: 4262-4269Crossref PubMed Scopus (91) Google Scholar). Recently, the human homologs of sprad1 (6.Freire R. Murguid J.R. Tarsounas M. Lowndes N.F. Moens P.B. Jackson S.P. Genes Dev. 1998; 12: 2560-2573Crossref PubMed Scopus (102) Google Scholar, 7.Parker A.E. Van de Weyer I. Laus M.C. Oostveen I. Yon J. Verhasselt P. Luyten W.H.M.L. J. Biol. Chem. 1998; 273: 18332-18339Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar, 8.Udell C.M. Lee S.K. Davey S. Nucleic Acids Res. 1998; 26: 3971-3976Crossref PubMed Scopus (35) Google Scholar),sprad9 (9.Lieberman H.B. Hopkins K.M. Nass M. Demetrick D. Davey S. Proc. Natl. Acad. Sci. U. S. A. 1996; 95: 13890-13895Crossref Scopus (107) Google Scholar), sprad17 (7.Parker A.E. Van de Weyer I. Laus M.C. Oostveen I. Yon J. Verhasselt P. Luyten W.H.M.L. J. Biol. Chem. 1998; 273: 18332-18339Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar), and sphus1(10.Kostrub C.F. Knudson K. Subramani S. Enoch T. EMBO J. 1998; 17: 2055-2066Crossref PubMed Scopus (100) Google Scholar) have been cloned, which has greatly improved the prospect of biochemical analysis of DNA damage checkpoint response in humans. Preliminary in vivo biochemical studies have already revealed some important information; hRAD91 becomes hyperphosphorylated upon DNA damage and makes a ternary complex with hRAD1 and hHUS1 proteins (11.Volkmer E. Karnitz L.M. J. Biol. Chem. 1999; 274: 567-570Abstract Full Text Full Text PDF PubMed Scopus (176) Google Scholar, 12.St. Onge R.P. Udell C.M. Casselman R. Davey S. Mol. Biol. Cell. 1999; 10: 1985-1995Crossref PubMed Scopus (129) Google Scholar). A similar complex was detected inSaccharomyces cerevisiae as well (13.Kondo T. Matsumoto K. Sugimoto K. Mol. Cell. Biol. 1999; 19: 1136-1143Crossref PubMed Scopus (111) Google Scholar), providing additional information about the early events in DNA damage checkpoint response reactions. In addition, hRAD1, which exhibits sequence homology toUstilago maydis Rec1 exonuclease (14.Thelen M.P. Onel K. Holloman W.K. J. Biol. Chem. 1994; 269: 133-139Abstract Full Text PDF Google Scholar), was reported to have a 3′ to 5′ nuclease activity (7.Parker A.E. Van de Weyer I. Laus M.C. Oostveen I. Yon J. Verhasselt P. Luyten W.H.M.L. J. Biol. Chem. 1998; 273: 18332-18339Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar), although another study failed to detect this activity (6.Freire R. Murguid J.R. Tarsounas M. Lowndes N.F. Moens P.B. Jackson S.P. Genes Dev. 1998; 12: 2560-2573Crossref PubMed Scopus (102) Google Scholar). In the present study, we have investigated the enzymatic properties of hRAD9. Surprisingly, we find that hRAD9, which does not have sequence motifs indicative of its function, possesses a 3′ to 5′ exonuclease activity. We suggest that this activity may be important in the damage sensing and signal transduction steps of the DNA damage checkpoint response reaction. The plasmid pcDNA3-AU1-hRAD9 (11.Volkmer E. Karnitz L.M. J. Biol. Chem. 1999; 274: 567-570Abstract Full Text Full Text PDF PubMed Scopus (176) Google Scholar, 12.St. Onge R.P. Udell C.M. Casselman R. Davey S. Mol. Biol. Cell. 1999; 10: 1985-1995Crossref PubMed Scopus (129) Google Scholar) was a kind gift from Dr. Larry M. Karnitz (Mayo Foundation, Rochester, MN). The hRAD9 gene was amplified from this plasmid by PCR using the primers 5′-CCGAGCTCGAGAATGAAGTGCCTGGTC and 5′-GATGCAAGCTTTCAGACTTCACCCTCA. The PCR product was digested withXhoI and HindIII and inserted into pRSET(b) from Invitrogen to obtain the His-tagged hRAD9 expression vector pRSET-hRAD9. Then, the BamHI-HindIII fragment carrying hRAD9 was isolated from pRSET-hRAD9 and inserted into pMalc-2 (New England Biolabs) to obtain the pMal-hRAD9 plasmid, which expresses the maltose-binding protein (MBP)-hRAD9 fusion protein. The various deletion derivatives of hRAD9 were generated from pMal-hRAD9 by PCR. To purify MBP-hRAD9, cell extract from DR153/pMal-hRAD9 was loaded onto an amylose affinity column, and after extensive washing, as described by the manufacturer (New England Biolabs), MBP-hRAD9 was eluted with 10 mm maltose. The protein was further purified by loading onto a DEAE-Sepharose column equilibrated with buffer R (20 mm Hepes-KOH, pH 7.8, 0.1 mm dithiothreitol, 0.1 mm EDTA, and 10% glycerol) and eluting with a salt gradient of 50 mm to 400 mm KCl in buffer R. MBP-hRAD9 came off the column at around 160 mm KCl. The peak fractions were combined, dialyzed against buffer R containing 50 mm KCl, and then subjected to a second round of DEAE chromatography as described above. The peak fractions were dialyzed against buffer R and stored at −80 °C. The deletion derivatives of hRAD9 in the form of MBP fusion were purified by an amylose affinity column followed by chromatography on DEAE and phenyl-Sepharose. For phenyl-Sepharose chromatography, the MBP-hRAD9 fractions from the DEAE column were dialyzed against buffer C (10 mm Tris-HCl, pH 7.5, 0.1 mm EDTA, and 10% glycerol) containing 1m ammonium sulfate and then loaded onto the phenyl-Sepharose column. After washing with buffer C containing 0.5m ammonium sulfate, the proteins were eluted by a gradient of 0.5 m ammonium sulfate in buffer C to 30% ethylene glycol in buffer C. MBP-hRAD9 deletion derivatives came off the column at about 30% ethylene glycol. After dialysis against buffer R, the proteins were stored at −80 °C. To establish that the exonuclease activity detected in MBP-hRAD9 was intrinsic to hRAD9, the purified MBP-hRAD9 was subjected to a variety of treatments. First, to obtain hRAD9 free of tag, 5 μg of MBP-hRAD9 was digested with 5 μg of Factor Xa in buffer R at 23 °C for 2 h. Then, 50 μl of amylose resin was added to the reaction mixture, which was incubated for another 2 h at 4 °C, the resin and bound proteins were removed by centrifugation, and the supernatant was used as the “hRAD9 fraction.” Second, to remove MBP-hRAD9 fusion protein from the MBP-hRAD9 preparations, 5 μg of the purified fusion protein was mixed with 50 μl of amylose resin for 2 h at 4 °C, the resin and bound material were removed by centrifugation, and the supernatant was used as the “MBP-hRAD9 depleted fraction.” Finally, the amylose resin-MBP-hRAD9 isolated in the previous procedure was resuspended in 25 μl of R buffer and digested with 5 μg of Factor Xa. The resin was removed by centrifugation, and the supernatant was used as the “hRAD9 recovered fraction.” In all of the Factor Xa treatments only about 50% of MBP-hRAD9 was cleaved as determined by SDS-PAGE and silver staining. The substrate used for most of our experiments was a 30-mer oligodeoxynucleotide, 5′-TCAGGGTGGCCAGCTGGCGCAGATCTGGCT-3′. The oligomer was labeled at the 5′ end using [γ-32P]ATP and polynucleotide kinase and at the 3′ terminus using [α-32P]ddATP and deoxynucleotidyl terminal transferase. To prepare a 3′-end-labeled substrate with a 3′-OH terminus, the oligomer was annealed to a complementary oligomer with a 34-nt extension in which the first non-complementary base was a G residue. Then, the 3′ end was labeled with [α-32P]dCTP using the Klenow fragment for extension. The extended oligomer (31-mer) was purified on a 10% denaturing polyacrylamide gel. For double-stranded oligomer substrate, the 31-mer was annealed with a complementary oligomer. In addition to these substrates, M13 single- and double-stranded forms were used to test for endonuclease activity. The standard reaction mixture contained 20 mm Hepes-KOH, pH 7.8, 10 mmMnCl2, 0.1 mm EDTA, and 10% glycerol (v/v), 0.3 pmol substrate, and 12 pmol (1 μg) of MBP-hRAD9. The reactions were performed at 37 °C and terminated by adding EDTA to 20 mm. Reaction products were separated on 10% denaturing polyacrylamide gels. Quantitative analyses of the data were conducted with a Storm 850 scanner and a PhosphorImager (Molecular Dynamics). The sequence of hRAD9 does not contain any sequence motif indicative of an enzymatic activity. However, genetic analyses in S. pombe implicate its homolog in the “damage-sensing” step of the DNA damage checkpoint response (4.Brondello J.M. Boddy M.N. Furnari B. Russell P. Mol. Cell. Biol. 1999; 19: 4262-4269Crossref PubMed Scopus (91) Google Scholar, 11.Volkmer E. Karnitz L.M. J. Biol. Chem. 1999; 274: 567-570Abstract Full Text Full Text PDF PubMed Scopus (176) Google Scholar). Therefore, we wished to investigate the interaction of this protein with DNA. In preliminary experiments, we noticed that DNA incubated with hRAD9 preparations was degraded and decided to characterize this activity in more detail. hRAD9 was expressed in Escherichia coli either in the form of (His)6-hRAD9 or MBP-hRAD9. Both forms were overproduced at reasonable levels and were soluble. The nuclease activity was detected with both the His- and MBP-tagged forms. However, even after a four-column purification procedure including a nickel affinity column, the (His)6-hRAD9 form contained minor contaminants (data not shown). Hence, we conducted most of our experiments with the MBP-hRAD9 recombinant protein. The protein was purified through an amylose affinity column and two ion exchange columns, and the peak fractions from the final step contained virtually pure MBP-hRAD9 as analyzed by SDS-PAGE and silver staining (Fig.1). When the purified protein was incubated with a 30-nt-long single-stranded DNA, the DNA was degraded exonucleolytically. With 5′-end-labeled substrate, the products were oligomers of gradually decreasing sizes (Fig. 2, lane 2), whereas with 3′-end-labeled DNA, the label was released in the form of a mononucleotide (Fig. 2, lane 4) indicating that hRAD9 is a 3′ to 5′ exonuclease. Because E. coli contains several 3′ to 5′ exonucleases, including exonuclease I, exonuclease VII, and RecJ, capable of degrading single-stranded DNA (15.Berlyn M.K.B. Microbiol. Mol. Biol. Rev. 1998; 62: 814-984Crossref PubMed Google Scholar), we considered the possibility that the exonuclease activity in our MBP-hRAD9 preparation might be due to a contaminant. To demonstrate that the activity was intrinsic to hRAD9, we analyzed the individual fractions from the last purification column for protein composition and nuclease activity. As seen in Fig. 3 the MBP-hRAD9 protein (panel A) co-elutes with the 3′ to 5′ exonuclease activity tested with either 5′-end-labeled (panel B) or 3′-end-labeled (panel C) substrates. These data do not unambiguously prove, but strongly indicate, that hRAD9 is a 3′ to 5′ exonuclease. This conclusion was further strengthened by the following series of experiments.Figure 33′ to 5′ exonuclease activity co-purifies with MBP-hRAD9. Column fractions from the second DEAE column were analyzed for protein composition and exonuclease activity.A, fractions analyzed by 10% SDS-PAGE and silver staining.B and C, exonuclease activity with 5′ (B)- and 3′ (C)-end-labeled substrates. The 3′-end-labeled substrate had dideoxy-AMP as the terminal nucleotide. T4 is a control lane containing DNA digested with 10 units of T4 DNA polymerase 3′ to 5′ exonuclease for 5 min at 37 °C.View Large Image Figure ViewerDownload Hi-res image Download (PPT) First, the MBP-hRAD9-associated nuclease activity could be removed by amylose resin, showing that the responsible protein bound to the resin (Fig. 4, lane 3). The nuclease activity was released from this resin by treating the bound proteins with Factor Xa, which cleaves at the junction of MBP and hRAD9 (Fig. 4,lane 5). Second, if the purified protein was treated with Factor Xa and then amylose-bound material was removed, the released protein showed the exonuclease activity (Fig. 4, lane 4). These data, taken together, show that the exonuclease binds to the amylose resin and can be released from the resin by Factor Xa. Since the possibility of an E. coli exonuclease binding to amylose and being released by Factor Xa is remote, we consider the data in Fig.4 as very strong evidence for hRAD9 being a 3′ to 5′ exonuclease. The sequence of hRAD9 does not show an obvious homology to any known nuclease, hence the active site could not be assigned to a specific region by sequence inspection. To locate the active site, we generated N- and C-terminal deletions of hRAD9 and tested them for nuclease activity. The results are shown in Fig. 5. The hRAD9(1–91) fragment and other C-terminal deletion derivatives containing this region are nearly as active as the full-length protein. Analysis of N-terminal deletion derivatives confirmed this conclusion and helped narrow down further the nuclease active site; hRAD9(92–391) lacked nuclease activity as expected, whereas hRAD9(52–391) was active. Thus, the results from hRAD9(1–91) combined with that obtained with hRAD9(52–391) places the nuclease active site within a stretch of 40 amino acids spanning amino acids 52 through 91. The reaction conditions affecting the hRAD9 exonuclease are summarized in TableI.The enzyme is 2.5-fold more active on single-stranded DNA than on double-stranded DNA and has no endonuclease activity as tested by nicking assay using plasmid DNA. The nuclease requires a divalent cation for activity, with the Mn2+being 2.5-fold more efficient than Mg2+. The activity is strongly reduced by moderate (100 mm) salt concentrations and product inhibited by high concentrations of a mononucleotide. Interestingly, the enzyme works more efficiently on substrates with 3′-OH termini than on substrates with 3′-dideoxy termini (Fig.2 B and Table I).Table ICharacterization of the nuclease activity of hRAD9Activity%Substrate Single-stranded 30-mer (3′-OH)100 Single-stranded 30-mer (ddAMP)40 Double-stranded 31-mer40 Single-stranded circular DNA<5 Double-stranded circular DNA<5Reaction conditions 10 mm MnCl2100 10 mm MgCl240 10 mmCaCl2<1 100 mm NaCl16 100 mm KCl13 20 mm EDTA<1 5 mm AMP2All values are expressed relative to the 3′ to 5′ exonuclease activity observed with 30-mer with 3′-OH terminus with 20 mmHepes-KOH, pH 7.8, 10 mm MnCl2, 0.1 mmEDTA, and 10% glycerol (v/v). The values for the covalently closed substrate indicate the percent that was converted to nicked circle with double-stranded DNA or the disappearance of single-stranded circular DNA upon incubation with MBP-hRAD9 in the reaction buffer. Open table in a new tab All values are expressed relative to the 3′ to 5′ exonuclease activity observed with 30-mer with 3′-OH terminus with 20 mmHepes-KOH, pH 7.8, 10 mm MnCl2, 0.1 mmEDTA, and 10% glycerol (v/v). The values for the covalently closed substrate indicate the percent that was converted to nicked circle with double-stranded DNA or the disappearance of single-stranded circular DNA upon incubation with MBP-hRAD9 in the reaction buffer. Immunoprecipitation analyses show that the hRAD1, hRAD9, and hHUS1 proteins make a radioresponsive checkpoint complex (11.Volkmer E. Karnitz L.M. J. Biol. Chem. 1999; 274: 567-570Abstract Full Text Full Text PDF PubMed Scopus (176) Google Scholar, 12.St. Onge R.P. Udell C.M. Casselman R. Davey S. Mol. Biol. Cell. 1999; 10: 1985-1995Crossref PubMed Scopus (129) Google Scholar). At present the precise role of this complex in damage sensing, damage processing, and signal transduction in the DNA damage checkpoint response is not known. Genetic analyses in both S. pombe and S. cerevisiae suggest that the complex functions in the early stages of the DNA damage checkpoint response (4.Brondello J.M. Boddy M.N. Furnari B. Russell P. Mol. Cell. Biol. 1999; 19: 4262-4269Crossref PubMed Scopus (91) Google Scholar, 13.Kondo T. Matsumoto K. Sugimoto K. Mol. Cell. Biol. 1999; 19: 1136-1143Crossref PubMed Scopus (111) Google Scholar, 16.Torre-Ruiz M.A. Green C.M. Lowndes N.F. EMBO J. 1998; 17: 2687-2698Crossref PubMed Scopus (129) Google Scholar). However, direct biochemical evidence for such a role has been lacking. Our finding that hRAD9 has an intrinsic 3′ to 5′ exonuclease function constitutes strong biochemical evidence that the complex interacts with DNA and hence most likely plays a role in the damage sensing step of the DNA damage checkpoint pathway. Further work with hRAD1 and hHUS1 and with the ternary translationally modified hRAD9 will help define more precisely the roles of the individual components as well as of the complex in the DNA damage checkpoint response in humans.
No takes yet. Share an insight, caveat, or question.
Bessho et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: